On November 5, 2024, the VIVA Foundation reported on presentations at the VIVA25 conference, including two-year results of the DEEPER OUS clinical trial for the Reflow Medical Spur® Peripheral Retrievable…
San Clemente, CA – July 1, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of…
San Clemente, CA – May 08, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces completion of enrollment in the DEEPER REVEAL clinical trial…
San Clemente, CA—Jan. 15, 2024 – Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the…
SAN CLEMENTE, CA — November 6, 2023 — Reflow Medical announced one-year results of the DEEPER OUS clinical trial (NCT04162418) evaluating the company’s Bare Temporary Spur Stent System. Results were…
SAN CLEMENTE, Calif. – – June 12, 2023 – – Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of…
SAN CLEMENTE, Calif. – – May 18, 2023 – – Reflow Medical, Inc. announced that it has received FDA commercial clearance for its coraCatheters™, a complete line of state-of-the-art microcatheters…
San Clemente, CA—Reflow Medical, Inc., a medical device company focused on cardiovascular disease announces that the first patient was successfully treated and enrolled in the DEEPER REVEAL investigational device exemption…
SAN CLEMENTE, June 28, 2022 — Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent…
San Clemente, CA—Reflow Medical, Inc. announces that it has completed patient enrollment in the DEEPER OUS clinical trial (NCT03807531) for the company’s Temporary Spur Stent System, a novel device that…
Recent Comments